Tamoxifen Metabolites Treatment Promotes ERα+ Transition to Triple Negative Phenotype in Vitro, Effects of LDL in Chemoresistance

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2024 Jul 22

PMID 39034849

Authors

Andrea Munoz-Ayala

Brenda Chimal-Vega

Nicolas Serafin-Higuera

Octavio Galindo-Hernandez

Gladys Ramirez-Rosales

Ivan Cordova-Guerrero

Luis Fernando Gomez-Lucas

Victor Garcia-Gonzalez

Affiliations

Soon will be listed here.

Abstract

Objective: Estrogen receptor-positive (ER+) breast cancer represents about 80% of cases, tamoxifen is the election neoadjuvant chemotherapy. However, a large percentage of patients develop chemoresistance, compromising recovery. Clinical evidence suggests that high plasmatic levels of low-density lipoproteins (LDL) could promote cancer progression. The present study analyzed the effect of LDL on the primary plasmatic active Tamoxifen's metabolites resistance acquisition, 4-hydroxytamoxifen (4OH-Tam) and 4-hydroxy-N-desmethyl-tamoxifen (endoxifen), in breast cancer ERα + cells (MCF-7).

Methods: Two resistant cellular variants, MCF-7Var-H and MCF-7Var-I, were generated by a novel strategy and their phenotype features were evaluated. Phenotypic assessment was performed by MTT assays, cytometry, immunofluorescence microscopy, zymography and protein expression analysis.

Results: MCF-7Var-H, generated only with tamoxifen metabolites, showed a critical down-regulation in hormone receptors, augmented migration capacity, metalloprotease 9 extracellular medium excretion, and a mesenchymal morphology in contrast with native MCF-7, suggesting the transition towards Triple-negative breast cancer (TNBC) phenotype. In contrast, MCF-7Var-I which was generated in a high LDL media, showed only a slight upregulation in ER and other less noticeable metabolic adaptations. Results suggest a potential role of transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) in phenotypic differences observed among variants.

Conclusion: LDL high or low concentrations during Tamoxifen´s metabolites chemoresistance acquisition leads to different cellular mechanisms related to chemoresistance. A novel adaptative cellular response associated with Nrf2 activity could be implicated.

References

Lu Y, Tong Y, Chen X, Shen K . Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients. Front Oncol. 2021; 11:638619. PMC: 8283966. DOI: 10.3389/fonc.2021.638619. View

Reinema F, Sweep F, Adema G, Peeters W, Martens J, Bussink J . Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer. Cancer Metab. 2023; 11(1):3. PMC: 9909892. DOI: 10.1186/s40170-023-00304-4. View

Lim Y, Desta Z, Flockhart D, Skaar T . Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005; 55(5):471-8. DOI: 10.1007/s00280-004-0926-7. View

Lu C, Lo Y, Chen C, Lin C, Tsai C, Chen P . VLDL and LDL, but not HDL, promote breast cancer cell proliferation, metastasis and angiogenesis. Cancer Lett. 2016; 388:130-138. DOI: 10.1016/j.canlet.2016.11.033. View

Gonzalez-Ortiz A, Galindo-Hernandez O, Hernandez-Acevedo G, Hurtado-Ureta G, Garcia-Gonzalez V . Impact of cholesterol-pathways on breast cancer development, a metabolic landscape. J Cancer. 2021; 12(14):4307-4321. PMC: 8176427. DOI: 10.7150/jca.54637. View

Raza U, Asif M, Rehman A, Sheikh A . Hyperlipidemia and hyper glycaemia in Breast Cancer Patients is related to disease stage. Pak J Med Sci. 2018; 34(1):209-214. PMC: 5857015. DOI: 10.12669/pjms.341.14841. View

Bi Z, Zhang Q, Fu Y, Seno A, Wadgaonkar P, Qiu Y . Cooperation between NRF2-mediated transcription and MDIG-dependent epigenetic modifications in arsenic-induced carcinogenesis and cancer stem cells. Semin Cancer Biol. 2021; 76:310-318. PMC: 8487439. DOI: 10.1016/j.semcancer.2021.03.030. View

Almahayni K, Spiekermann M, Fiore A, Yu G, Pedram K, Mockl L . Small molecule inhibitors of mammalian glycosylation. Matrix Biol Plus. 2022; 16:100108. PMC: 9713294. DOI: 10.1016/j.mbplus.2022.100108. View

Cullinan S, Diehl J . PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J Biol Chem. 2004; 279(19):20108-17. DOI: 10.1074/jbc.M314219200. View

10.

Rodrigues Dos Santos C, Fonseca I, Dias S, Mendes de Almeida J . Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC Cancer. 2014; 14:132. PMC: 3942620. DOI: 10.1186/1471-2407-14-132. View

11.

Kumar H, Kumar R, Bhattacharjee D, Somanna P, Jain V . Role of Nrf2 Signaling Cascade in Breast Cancer: Strategies and Treatment. Front Pharmacol. 2022; 13:720076. PMC: 9098811. DOI: 10.3389/fphar.2022.720076. View

12.

Meisner A, Fekrazad M, Royce M . Breast disease: benign and malignant. Med Clin North Am. 2008; 92(5):1115-41, x. DOI: 10.1016/j.mcna.2008.04.003. View

13.

Wolfe A, Atkinson R, Reddy J, Debeb B, Larson R, Li L . High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2015; 91(5):1072-80. PMC: 4801170. DOI: 10.1016/j.ijrobp.2014.12.039. View

14.

Fragomeni S, Sciallis A, Jeruss J . Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am. 2017; 27(1):95-120. PMC: 5715810. DOI: 10.1016/j.soc.2017.08.005. View

15.

Antalis C, Arnold T, Rasool T, Lee B, Buhman K, Siddiqui R . High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Res Treat. 2009; 122(3):661-70. DOI: 10.1007/s10549-009-0594-8. View

16.

Rojo de la Vega M, Chapman E, Zhang D . NRF2 and the Hallmarks of Cancer. Cancer Cell. 2018; 34(1):21-43. PMC: 6039250. DOI: 10.1016/j.ccell.2018.03.022. View

17.

Robertson H, Dinkova-Kostova A, Hayes J . NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of Tumourigenesis. Cancers (Basel). 2020; 12(12). PMC: 7761610. DOI: 10.3390/cancers12123609. View

18.

Mills J, Rutkovsky A, Giordano A . Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. Curr Opin Pharmacol. 2018; 41:59-65. PMC: 6454890. DOI: 10.1016/j.coph.2018.04.009. View

19.

Simigdala N, Gao Q, Pancholi S, Roberg-Larsen H, Zvelebil M, Ribas R . Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer. Breast Cancer Res. 2016; 18(1):58. PMC: 4888666. DOI: 10.1186/s13058-016-0713-5. View

20.

Paolillo M, Schinelli S . Extracellular Matrix Alterations in Metastatic Processes. Int J Mol Sci. 2019; 20(19). PMC: 6802000. DOI: 10.3390/ijms20194947. View